Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study.

PubWeight™: 1.67‹?› | Rank: Top 3%

🔗 View Article (PMC 4157936)

Published in Ann Intern Med on September 24, 2013

Authors

Katherine A Moon, Eliseo Guallar, Jason G Umans, Richard B Devereux, Lyle G Best, Kevin A Francesconi, Walter Goessler, Jonathan Pollak, Ellen K Silbergeld, Barbara V Howard, Ana Navas-Acien

Articles citing this

Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in Colorado residents. Environ Health Perspect (2014) 1.13

Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J (2014) 1.06

Arsenic in Drinking Water and Mortality for Cancer and Chronic Diseases in Central Italy, 1990-2010. PLoS One (2015) 0.95

Low-dose arsenic: in search of a risk threshold. Environ Health Perspect (2014) 0.93

Association of arsenic with adverse pregnancy outcomes/infant mortality: a systematic review and meta-analysis. Environ Health Perspect (2015) 0.92

Environmental factors in cardiovascular disease. Nat Rev Cardiol (2015) 0.92

Effects of in Utero Exposure to Arsenic during the Second Half of Gestation on Reproductive End Points and Metabolic Parameters in Female CD-1 Mice. Environ Health Perspect (2015) 0.89

Dietary sources of methylated arsenic species in urine of the United States population, NHANES 2003-2010. PLoS One (2014) 0.89

The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study. Epidemiology (2015) 0.89

Arsenic Exposure and Subclinical Endpoints of Cardiovascular Diseases. Curr Environ Health Rep (2014) 0.87

Arsenic induces structural and compositional colonic microbiome change and promotes host nitrogen and amino acid metabolism. Toxicol Appl Pharmacol (2015) 0.85

Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. Environ Health Perspect (2015) 0.84

Metal mixtures in urban and rural populations in the US: The Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study. Environ Res (2016) 0.83

In search of "just right": the challenge of regulating arsenic in rice. Environ Health Perspect (2015) 0.82

MDI Biological Laboratory Arsenic Summit: Approaches to Limiting Human Exposure to Arsenic. Curr Environ Health Rep (2015) 0.81

Biomarker Levels of Toxic Metals among Asian Populations in the United States: NHANES 2011-2012. Environ Health Perspect (2016) 0.81

Interaction between arsenic exposure from drinking water and genetic polymorphisms on cardiovascular disease in Bangladesh: a prospective case-cohort study. Environ Health Perspect (2015) 0.80

Risk of death from cardiovascular disease associated with low-level arsenic exposure among long-term smokers in a US population-based study. Toxicol Appl Pharmacol (2015) 0.80

Cardiovascular disease and arsenic exposure in Inner Mongolia, China: a case control study. Environ Health (2015) 0.80

Environmental Exposures and Cardiovascular Disease: A Challenge for Health and Development in Low- and Middle-Income Countries. Cardiol Clin (2017) 0.80

Gene-arsenic interaction in longitudinal changes of blood pressure: Findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol Appl Pharmacol (2015) 0.79

Blood Pressure Changes in Relation to Arsenic Exposure in a U.S. Pregnancy Cohort. Environ Health Perspect (2015) 0.79

Relation of dietary inorganic arsenic to serum matrix metalloproteinase-9 (MMP-9) at different threshold concentrations of tap water arsenic. J Expo Sci Environ Epidemiol (2015) 0.79

Rice consumption and risk of cardiovascular disease: results from a pooled analysis of 3 U.S. cohorts. Am J Clin Nutr (2014) 0.78

Poultry Consumption and Arsenic Exposure in the U.S. Population. Environ Health Perspect (2016) 0.78

Associations between Blood and Urine Arsenic Concentrations and Global Levels of Post-Translational Histone Modifications in Bangladeshi Men and Women. Environ Health Perspect (2016) 0.77

Human exposure to dietary inorganic arsenic and other arsenic species: State of knowledge, gaps and uncertainties. Sci Total Environ (2016) 0.77

Arsenic and cardiovascular disease: new evidence from the United States. Ann Intern Med (2013) 0.77

Linkage Analysis of Urine Arsenic Species Patterns in the Strong Heart Family Study. Toxicol Sci (2015) 0.77

Arsenic Exposure Increases Monocyte Adhesion to the Vascular Endothelium, a Pro-Atherogenic Mechanism. PLoS One (2015) 0.76

Genetic deletion of LXRα prevents arsenic-enhanced atherosclerosis, but not arsenic-altered plaque composition. Toxicol Sci (2014) 0.76

Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med (2014) 0.76

Peripheral Arterial Disease and Its Association With Arsenic Exposure and Metabolism in the Strong Heart Study. Am J Epidemiol (2016) 0.75

Potential sources and racial disparities in the residential distribution of soil arsenic and lead among pregnant women. Sci Total Environ (2016) 0.75

Arsenic Exposure and Predicted 10-Year Atherosclerotic Cardiovascular Risk Using the Pooled Cohort Equations in U.S. Hypertensive Adults. Int J Environ Res Public Health (2016) 0.75

Influence of Arsenic on Global Levels of Histone Posttranslational Modifications: a Review of the Literature and Challenges in the Field. Curr Environ Health Rep (2016) 0.75

Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis. Toxicol Lett (2016) 0.75

Response to "Comment on 'Association between Lifetime Exposure to Inorganic Arsenic in Drinking Water and Coronary Heart Disease in Colorado Residents'". Environ Health Perspect (2015) 0.75

Arsenic Promotes NF-Κb-Mediated Fibroblast Dysfunction and Matrix Remodeling to Impair Muscle Stem Cell Function. Stem Cells (2016) 0.75

The "Typical" Asian Diet Is Anything But: Differences in Dietary Exposure to Metals among Subgroups of U.S. Asians. Environ Health Perspect (2017) 0.75

The Microbiome and Sustainable Healthcare. Healthcare (Basel) (2015) 0.75

Estimation of Inorganic Arsenic Exposure in Populations With Frequent Seafood Intake: Evidence From MESA and NHANES. Am J Epidemiol (2016) 0.75

[Environmental pollution, climate variability and climate change: a review of health impacts on the Peruvian population]. Rev Peru Med Exp Salud Publica (2014) 0.75

Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals. Biomed Res Int (2016) 0.75

Endothelial function and serum concentration of toxic metals in frequent consumers of fish. PLoS One (2014) 0.75

Maternal and infant inflammatory markers in relation to prenatal arsenic exposure in a U.S. pregnancy cohort. Environ Res (2017) 0.75

Hyperglycemia enhances arsenic-induced platelet and megakaryocyte activation. J Transl Med (2017) 0.75

Low-dose dose-response for reduced cell viability after exposure of human keratinocyte (HEK001) cells to arsenite. Toxicol Rep (2016) 0.75

Mining and Environmental Health Disparities in Native American Communities. Curr Environ Health Rep (2017) 0.75

Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. PLoS One (2017) 0.75

Chronic arsenic exposure and risk of carotid artery disease: The Strong Heart Study. Environ Res (2017) 0.75

Articles cited by this

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62

A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41

The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol (1990) 4.89

Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation (1999) 3.82

Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ (2011) 3.34

Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect (1999) 3.23

Gender differences in the disposition and toxicity of metals. Environ Res (2006) 2.91

Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol (2005) 2.90

Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol (2007) 2.36

Urinary arsenic concentration adjustment factors and malnutrition. Environ Res (2007) 2.14

Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol (1996) 2.12

Arsenic in drinking water and adult mortality: a population-based cohort study in rural Bangladesh. Epidemiology (2009) 2.11

Public health responses to arsenic in rice and other foods. JAMA Intern Med (2013) 2.09

Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect (2012) 2.05

Arsenic and cardiovascular disease. Toxicol Sci (2008) 1.90

Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health (2007) 1.87

Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water. Am J Public Health (2004) 1.82

Correlation between the arsenic concentrations in the air and the SMR of lung cancer. Environ Health Prev Med (2008) 1.78

Risk factors for coronary heart disease in diabetic and nondiabetic Native Americans. The Strong Heart Study. Diabetes (1992) 1.67

Prevalence of arsenic exposure from drinking water and awareness of its health risks in a Bangladeshi population: results from a large population-based study. Environ Health Perspect (2006) 1.65

Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol (2005) 1.64

Urine arsenic concentrations and species excretion patterns in American Indian communities over a 10-year period: the Strong Heart Study. Environ Health Perspect (2009) 1.63

Urine arsenic and prevalent albuminuria: evidence from a population-based study. Am J Kidney Dis (2012) 1.59

Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health (1994) 1.52

Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect (2006) 1.51

Arsenic in drinking water and stroke hospitalizations in Michigan. Stroke (2010) 1.49

Arsenic exposure and hypertension: a systematic review. Environ Health Perspect (2011) 1.44

Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res (2009) 1.41

The temporal stability of arsenic concentrations in well water in western Nevada. Environ Res (2004) 1.34

Arsenic exposure and cardiovascular disease: an updated systematic review. Curr Atheroscler Rep (2012) 1.32

Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based epidemiological study. Anal Methods (2012) 1.27

Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Am J Epidemiol (2012) 1.25

Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ Health Perspect (2003) 1.22

Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol Appl Pharmacol (2006) 1.21

What is the best biomarker to assess arsenic exposure via drinking water? Environ Int (2011) 1.20

Human retention studies with 74As. Toxicol Appl Pharmacol (1980) 1.17

Recruitment of American Indians in epidemiologic research: the Strong Heart Study. Am Indian Alsk Native Ment Health Res (2000) 1.16

A morbid condition involving cardio-vascular, broncho-pulmonary, digestive and neural lesions in children and young adults after dietary arsenic exposure. Zentralbl Bakteriol B (1980) 1.14

Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol (2004) 1.14

Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health (2001) 1.13

Longitudinal investigation of exposure to arsenic, cadmium, and lead in drinking water. Environ Health Perspect (2000) 1.11

Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan. Sci Total Environ (2009) 1.09

Blackfoot disease and arsenic: a never-ending story. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev (2005) 1.09

Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicol Appl Pharmacol (2009) 1.08

A case-cohort study examining lifetime exposure to inorganic arsenic in drinking water and diabetes mellitus. Environ Res (2013) 1.06

Arsenic exposure and incidence of type 2 diabetes in Southwestern American Indians. Am J Epidemiol (2013) 1.05

The relationship between urine osmolality and specific gravity. Am J Med Sci (2002) 1.01

Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol (2009) 1.00

Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study. Int J Epidemiol (2011) 0.97

Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. Environ Res (2012) 0.97

Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ Res (2011) 0.92

Heritability and preliminary genome-wide linkage analysis of arsenic metabolites in urine. Environ Health Perspect (2013) 0.92

Urine arsenic concentrations in healthy adults as indicators of environmental contamination: relation with some pathologies. Sci Total Environ (1998) 0.90

Well water arsenic exposure, arsenic induced skin-lesions and self-reported morbidity in Inner Mongolia. Int J Environ Res Public Health (2009) 0.90

Measured versus modeled dietary arsenic and relation to urinary arsenic excretion and total exposure. J Expo Sci Environ Epidemiol (2013) 0.89

Increased mortality associated with well-water arsenic exposure in Inner Mongolia, China. Int J Environ Res Public Health (2009) 0.88

The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan. Water Res (2010) 0.85

Evaluation of toxic elements in scalp hair samples of myocardial infarction patients at different stages as related to controls. Biol Trace Elem Res (2009) 0.84

Arsenic in drinking water and mortality in the Southern Great Plain, Hungary. Environ Geochem Health (1991) 0.83

Medical geochemistry research in Spissko-Gemerské rudohorie Mts., Slovakia. Environ Geochem Health (2008) 0.83

Association of environmental toxic elements in biological samples of myocardial infarction patients at different stages. Biol Trace Elem Res (2010) 0.79

Is arsenic a contributor to CKD? Am J Kidney Dis (2013) 0.77

Articles by these authors

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86

Body-mass index and mortality in Korean men and women. N Engl J Med (2006) 7.50

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 6.87

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15

Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation (2009) 5.82

A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med (2013) 5.52

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care (2008) 5.43

Enough is enough: Stop wasting money on vitamin and mineral supplements. Ann Intern Med (2013) 5.28

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55

Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49

Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20

Retracted Expression of concern: Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med (2008) 3.93

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA (2002) 3.88

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85

Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA (2008) 3.83

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 3.70

Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65

Rapid response systems: a systematic review. Crit Care Med (2007) 3.51

Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation (2006) 3.47

Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med (2014) 3.30

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27

Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24

Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care (2003) 3.21

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15

Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect (2006) 3.11

Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol (2005) 3.10

Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ (2003) 3.05

Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97

Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA (2003) 2.97

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96

Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol (2005) 2.90

Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90

Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med (2010) 2.89

Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation (2004) 2.83

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol (2009) 2.82

Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care (2008) 2.76

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69

Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med (2005) 2.68

Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68

Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62

Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55

Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol (2008) 2.52

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50

Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49

Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma (2006) 2.48

Roxarsone, inorganic arsenic, and other arsenic species in chicken: a U.S.-based market basket sample. Environ Health Perspect (2013) 2.47

Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect (2006) 2.44

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation (2008) 2.44

Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43

Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care (2003) 2.40

Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr (2006) 2.40

Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40

Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38

Secondhand smoke exposure among women and children: evidence from 31 countries. Am J Public Health (2008) 2.37

Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension (2004) 2.36

Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care (2007) 2.33

Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum (2009) 2.33

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29

Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 2.28

Retracted Expression of concern: Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med (2009) 2.28

In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (2007) 2.27

Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24

Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23